Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EXG-7001
- Development stage
- Preclinical
- Lead developer
- Elixirgen Therapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
EXG-7001 is a full-length dystrophin mRNA therapeutic being developed for the treatment of Duchenne muscular dystrophy. The drug is designed to deliver functional dystrophin protein via mRNA technology, aiming to address the underlying cause of Duchenne muscular dystrophy by restoring or replacing the missing or defective dystrophin in patients. The developer is Elixirgen Therapeutics, and as of the latest available information, EXG-7001 is in preclinical development[2][4].
- Brand names
- Bobcat mRNA
- Other names
- Bobcat mRNA TMBobcat® mRNA
02
Targets
DMD (Dystrophin)
Beyond the preview
Go deeper on EXG-7001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EXG-7001.